Contribute Try STAT+ Today

Good morning, everyone, and how are you today? We are doing just fine, thank you, despite the cloudy skies looming over the Pharmalot campus, where things have settled down now that the short person is hunched over a laptop and the official mascot has assumed his formal snoozing positions. As for us, we are dutifully concocting a few needed cups of stimulation as we dig in for another busy day. No doubt, you can relate. So time to get cracking. As always, we have assembled some items of interest. So hoist your own cup to a successful day, and drop us a line when something interesting arises. …

Moderna (MRNA) reported that its Covid-19 vaccine was effective in children aged 12 to 17 in a new study, a finding that could clear the way for a second shot for use in adolescents, The Associated Press writes. The company said the vaccine induced immune responses among children that were comparable to those seen in a study of adults last year. There were no cases of symptomatic Covid-19 among vaccine recipients, suggesting 100% vaccine efficacy in adolescents, though overall very few among the 3,700 children in the study got sick.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.